Arbutus Biopharma Corporation ABUS Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's financing cash flow?
- Arbutus Biopharma Corporation (ABUS) reported financing cash flow of $11.62M in Q1 2026.
- How has Arbutus Biopharma Corporation's financing cash flow changed year-over-year?
- Arbutus Biopharma Corporation's financing cash flow increased by 317.3% year-over-year, from $2.78M to $11.62M.
- What is the long-term trend for Arbutus Biopharma Corporation's financing cash flow?
- Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's financing cash flow has grown at a -54.8% compound annual growth rate (CAGR), from $137.24M to $5.72M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.